CVRx Barostim Hypertension Pivotal Trial

This study is currently recruiting participants.
Verified August 2013 by CVRx, Inc.
Information provided by (Responsible Party):
CVRx, Inc. Identifier:
First received: August 31, 2012
Last updated: August 23, 2013
Last verified: August 2013

The Barostim™ Hypertension Pivotal Trial is a prospective, randomized, controlled trial to demonstrate the safety and efficacy of the Barostim Neo system in subjects with resistant hypertension.

Condition Intervention
Uncontrolled Hypertension
Device: Neo Baroreflex Activation Therapy System

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: CVRx Barostim Hypertension Pivotal Trial

Resource links provided by NLM:

Further study details as provided by CVRx, Inc.:

Primary Outcome Measures:
  • Primary Safety Objective [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
    To demonstrate the safety of the Neo system by reporting all adverse events that are complications between implant and 30 days post-implant in the device arm. The incidence of adverse events will be categorized by relatedness.

  • Primary Efficacy Objective [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To demonstrate a significant reduction between the two treatment arms of protocol defined automated office cuff systolic blood pressure (SBP) from baseline to 6 months post-activation.

Secondary Outcome Measures:
  • Secondary Efficacy Objective 1 [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To demonstrate a significant reduction within the device arm of office cuff systolic blood pressure (SBP) between baseline and 12 months post-activation.

  • Secondary Efficacy Objective 2 [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To demonstrate a significant reduction within the device arm of 24-hour ambulatory systolic blood pressure (SBP) between baseline and 12 months post-activation.

  • Secondary Safety Objective [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    To demonstrate the safety of the Neo system by reporting all hypertensive emergencies from activation to 6 months post activation. The incidence of hypertensive emergencies will be categorized by study arm.

Estimated Enrollment: 310
Study Start Date: January 2013
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Neo Baroreflex Activation Therapy System
Patients are randomized to receive Neo Baroreflex Activation Therapy System device plus optimal medical management.
Device: Neo Baroreflex Activation Therapy System
Other Names:
  • Neo System
  • Barostim Neo System
No Intervention: Medical Management Arm
Patients are randomized to receive optimal medical management alone.


Ages Eligible for Study:   21 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria Highlights:

  • Age at least 21 years and no more than 80 years at the time of randomization.
  • On four or more maximally tolerated anti-hypertensive medications, one of which is a diuretic. The antihypertensive medication regimen must remain unchanged for 4 weeks prior to screening and must be expected to remain unchanged for at least 6 months during follow-up.
  • Protocol defined systolic blood pressure greater than or equal to 160 mmHg.
  • Protocol defined 24-hour Ambulatory Blood Pressure Monitoring (ABPM) greater than or equal to 135 mmHg.
  • Serum estimated glomerular filtration rate (eGFR) > 29 mL/min/1.73 m^2.
  • Appropriate surgical candidate.
  • Women of childbearing potential must use a medically accepted method of birth control and agree to continue use of this method for the duration of the study. Women of childbearing potential must have a negative pregnancy test within 14 days prior to randomization.

Exclusion Criteria Highlights:

  • Known or suspected baroreflex failure or autonomic neuropathy.
  • Myocardial infarction, hypertensive crisis, symptomatic orthostatic hypotension, unstable angina, syncope, or cerebral vascular accident within the 3 months.
  • Hypertension secondary to an identifiable and treatable cause other than sleep apnea.
  • Prior surgery, radiation, or endovascular stent placement in the carotid sinus region.
  Contacts and Locations
Please refer to this study by its identifier: NCT01679132

Contact: Tom Moore 763-416-2352

United States, Arizona
Arizona Heart Rhythm Research Center Recruiting
Phoenix, Arizona, United States, 85006
Contact: Wendy Schwoegler    602-456-2342   
Principal Investigator: Vijay Swarup         
United States, California
University of Southern California Recruiting
Los Angeles, California, United States, 90033
Contact: Christian Romero    323-442-5322   
Principal Investigator: Karen Woo         
United States, District of Columbia
George Washington University Recruiting
Washington, District of Columbia, United States, 20037
Contact: Cathy Garey    202-741-3168   
Principal Investigator: Gregory Trachiotis         
United States, Florida
Florida Hospital Cardiovascular Institute Recruiting
Orlando, Florida, United States, 32803
Contact: Carol Stastny    407-303-5600 ext 1103439   
Principal Investigator: Harischandra Karunaratne         
Florida Cardiovascular Institute Recruiting
Tampa, Florida, United States, 33606
Contact: Courtney Lee    813-353-8535   
Principal Investigator: Fadi Matar         
United States, Louisiana
Cardiovascular Institute of the South Recruiting
Houma, Louisiana, United States, 70361
Contact: Deanna Benoit    985-873-5613   
Principal Investigator: Richard Abben         
United States, Michigan
Cardiac and Vascular Research Center of Northern Michigan Recruiting
Petosky, Michigan, United States, 49770
Contact: Jennifer LaLonde    231-487-9185   
Principal Investigator: Harry Colfer         
Michigan CardioVascular Institute Recruiting
Saginaw, Michigan, United States, 48601
Contact: Tacey Gauthier    989-907-8031   
Principal Investigator: Naveed Akhtar         
United States, Nevada
University Medical Center of Southern Nevada Recruiting
Las Vegas, Nevada, United States, 89102
Contact: Luzviminda Dizon    702-383-2585   
Principal Investigator: Chowdhury Ahsan         
United States, Oklahoma
Oklahoma Heart hospital Recruiting
Oklahoma City, Oklahoma, United States, 73120
Contact: Bonnie Miller    405-608-1280   
Principal Investigator: Branislov Schifferdecker         
United States, Pennsylvania
Allegheny General Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15212
Contact: Sheila Bernardini    412-359-5600 ext 1103439   
Principal Investigator: Srinivas Murali         
United States, Wisconsin
Aspirus Wausau Hospital Recruiting
Wausau, Wisconsin, United States, 54401
Contact: Jeff Kaliebe    715-847-2273 ext 52639   
Principal Investigator: German Larrain         
Sponsors and Collaborators
CVRx, Inc.
Study Chair: George Bakris, MD The University of Chicago Medicine
Study Chair: John Bisognano, MD University of Rochester
Study Chair: Fred Weaver, MD Keck School of Medicine of the University of Southern California
Study Chair: William Abraham, MD Ohio State University
  More Information

No publications provided

Responsible Party: CVRx, Inc. Identifier: NCT01679132     History of Changes
Other Study ID Numbers: 360039
Study First Received: August 31, 2012
Last Updated: August 23, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by CVRx, Inc.:
High Blood Pressure
Blood Pressure
Cardiovascular Disease
Resistant Hypertension

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on April 16, 2014